Xinkanghe Biological Medicine announced the completion of a tens of millions of dollars Series B financing.

Suzhou Xinkanghe Biological Pharmaceutical Technology Co., Ltd. ("Xinkanghe Biological Pharmaceutical") announced that it has recently completed a financing round of tens of millions of dollars.BThis round of financing was led by Chende Capital, with participation from Sanzheng Health Investment, China-Singapore Industrial Investment, and others. Existing shareholder Hetang Venture Capital continues to support. The funds raised in this round will mainly be used to accelerate the development and advancement of the company's clinical projects and several preclinical projects.

XinkangheCEOWang Yaning stated:"We are very honored to have received the high trust and strong support of many excellent investment institutions in this round of financing. This round of financing will play a crucial role in accelerating the advancement of the company's clinical trial projects and further strengthening the overall level of the company's product pipeline. We will work hand in hand with investors to promote the development of innovative drugs aimed at the global market, striving to build a leading new drug research and development company rooted in China with a global vision.

Xinkanghe Biological Pharmaceutical was established in2015year, founded by Academician Dong Chen, the founding director of the Shanghai Immunotherapy Innovation Research Institute and a professor at Tsinghua University School of Medicine, an internationally renowned immunologist. The company insists on basing its research on cutting-edge international immunology, focusing on the development of macromolecular drugs in the fields of autoimmune diseases and immuno-oncology, committed to creating innovative drugs originating from China, targeting the global market, and possessing independent intellectual property rights, providing patients with globally innovative or best-in-class treatment solutions.

In nearly six years since its establishment, Xinkanghe has gathered a core team with years of deep cultivation in research and development, processes, and clinical fields, adhering to the research and development philosophy of "innovation, precision, quality, and focus." Through solid basic science combined with translational medicine, it has multiple research and development projects with independent intellectual property rights, and its product pipeline covers a rich range of indications in autoimmune and oncology fields. The innovative antibody project has entered multiple clinical stages.IL17A/FAt the same time,First-in-Classthe first innovative drug project has been submitted for IND in China and the United States,IND, and is expected to enter the clinical trial phase soon.

The leading investor Chende Capital stated:"We highly recognize Academician Dong Chen and the Xinkanghe research and development team's profound academic accumulation and experience in antibody drug development in the field of immunology. Xinkanghe has a unique product pipeline and an innovative technology platform, with several candidate molecules expected to become globally innovative or best-in-class drugs. We look forward to working with Xinkanghe to quickly bring these highly promising products to market, benefiting patients worldwide."

Chende Capital

Chende Capital is an investment institution focused on innovative medical technology and cutting-edge biotechnology sub-sectors, managed and operated by a professional team with extensive medical industry backgrounds, managing multiple RMB and USD funds.

Based on extensive industrial resources in the global medical field and years of deep cultivation, we can quickly gain insights into the latest international technological trends, seize global investment opportunities, and influence the future development direction of the Chinese medical market. Chende Capital adheres to the investment philosophy of "focus, excellence, and reputation," committed to building top enterprises in the medical field and creating the best returns for investors.

Sanzheng Health Investment

Sanzheng Health Investment is a private equity investment fund focused on the medical and health industry. We focus on unmet clinical needs, invest in innovative medical health technologies, promote their clinical transformation and industrialization, saving more lives while improving the quality of life for patients. Sanzheng Health Investment relies on deep resources in clinical, industrial, and policy areas, working with partners to create great health technology enterprises.

China-Singapore Industrial Investment

China-Singapore Industrial Investment, fully known as China-Singapore Suzhou Industrial Park Industrial Investment Co., Ltd., is a wholly-owned subsidiary of China-Singapore Suzhou Industrial Park Development Group Co., Ltd. (referred to as "China-Singapore Group"), and the parent company of China-Singapore Suzhou Industrial Park Private Equity Fund Management Co., Ltd. (referred to as "China-Singapore Capital"). China-Singapore Industrial Investment focuses on the development strategy of China-Singapore Group, based on the development area, focusing on life sciences, artificial intelligence, nanotechnology applications, and other fields, deeply exploring investment opportunities, and empowering invested enterprises from multiple dimensions to promote their leapfrog development.

Hetang Venture Capital

Hetang Venture CapitalFounded in2001year, it is the investment management platform company for technology transfer and achievement transformation of Tsinghua University. Hetang Venture Capital has long adhered to the goal of investing in technology innovation enterprises, focusing on investing in high-tech and high-growth enterprises with core competitiveness in the startup and growth stages, concentrating on the incubation and investment of Tsinghua University's technology achievements, covering fields such as information technology, life sciences, and clean technology.